Bayerische Motoren Werke ADR (BMWYY)

The opioid crisis remains one of the most pressing public health challenges of our time. While synthetic opioids like fentanyl play a crucial role in managing severe pain, their high abuse potential has led to a growing demand for smarter, safer delivery systems. As policymakers, healthcare providers, and regulators seek solutions that balance medical necessity with public safety, innovative technologies are emerging that could reshape how these powerful drugs are administered.

While studying why non-human primates aren’t as likely to suffer from certain cancers when compared to humans, UC Davis scientists discovered a genetic mutation that could explain this anomaly. Their findings were published in the Nature Communications journal. This discovery could open the door to the development of more powerful treatments for cancer.

In a recent webinar hosted by Allele Capital, Soligenix (NASDAQ: SNGX) executives Dr. Christopher Schaber and Dr. Christopher Pullion shared detailed updates on the company’s HyBryte(TM) (synthetic hypericin) clinical development ( https://ibn.fm/dz7eO ). The event offered an in-depth look at Soligenix’s ongoing confirmatory phase 3 trial for cutaneous T-cell lymphoma (“CTCL”), a rare non-Hodgkin’s lymphoma, and discussed promising data emerging from an investigator-initiated study conducted at the University of Pennsylvania. Soligenix, a late-stage biopharmaceutical company, is dedicated to developing and commercializing treatments for rare diseases and unmet medical needs, and HyBryte(TM) represents the company’s lead asset aimed at transforming the treatment landscape for CTCL.

Oragenics (NYSE American: OGEN) a developer of intranasal pharmaceuticals for neurological disorders, has entered into a placement agency agreement for the sale of up to 800,000 shares of Series H Convertible Preferred Stock and accompanying Warrants, priced at $25.00 per unit. Each Warrant allows purchase of an additional Preferred share at $25.00, with Preferred shares convertible into common stock at $2.50. Gross proceeds could total $20 million, which will support ONP-2 concussion trials, R&D, repayment of a $3 million bridge note, and general corporate needs. Dawson James Securities, Inc. is acting as sole placement agent, with closing expected on or about July 2, 2025.

Existing scientific information shows that pesticides are toxic to the microorganisms in the gut, and a new preclinical study has mapped the specific impacts that compounds in pesticides have on microbes in the human digestive system. One surprising finding emerged regarding how these pesticide compounds affect the inflammatory system in the body.

Nutriband (NASDAQ: NTRB) has been added to the Russell Microcap, Russell Microcap Growth, Russell 3000E, and Russell 3000E Growth Indexes as part of the 2025 Russell indexes reconstitution. CEO Gareth Sheridan called the inclusion a reflection of market recognition and momentum behind the company’s AVERSA pipeline, particularly AVERSA Fentanyl, which has potential peak annual U.S. sales between $80 million and $200 million. Russell indexes, maintained by FTSE Russell, benchmark approximately $10.6 trillion in assets and are widely used by investment managers and institutions.

NextPlat (NASDAQ: NXPL, NXPLW) released a shareholder letter from Interim CEO expressing confidence in the company’s future following the recent passing of CEO and Chairman Charles M. Fernandez. The letter highlights internal reviews, meetings with subsidiary leaders, and plans for increased focus, coordination, and strategic investment to build on the company’s existing foundation and drive long-term value creation.

Panda Hub announces expansion across 15 U.S. states and 2 Canadian provinces, offering mobile car detailing services with certified professionals and sustainable practices.

University of Plymouth researchers in the UK have identified the proteins that underlie the growth and development of common brain tumors. Their findings could, in the long run, trigger the development of new treatments which are less invasive.

According to recent industry data, interest in pre-owned vehicles has surged due to ongoing supply chain constraints affecting new car production and rising inflation rates. Select Automotive’s latest move positions the dealership as a key player in addressing this gap, with dozens of new arrivals added to its lot this month alone.

Adageis offers providers tools that simplify operations and improve financial performance as healthcare shifts further toward value-based care. “One of the core advantages Adageis offers is the clarity it brings to complex healthcare systems. Its platform is designed to be simple for clinics to navigate, allowing physicians and administrators to see which of their services yield the highest value. This supports decision-making around treatment priorities while maintaining quality standards,” reads a recent article. “Instead of relying on outside consultants or navigating spreadsheets, practices can use the software to pinpoint which services align best with revenue and care standards. The platform aims to make this information more accessible to staff without a technical background.”

Annovis Bio (NYSE: ANVS), a late-stage clinical company focused on therapies for neurodegenerative diseases, announced its leadership will attend the Alzheimer’s Association International Conference (AAIC) from July 27–31, 2025, in Toronto. The company will present four scientific posters detailing progress on its Alzheimer’s clinical program and pharmacokinetic data for its lead candidate, buntanetap. Topics include the design of a Phase III trial, efficacy and safety data, and comparative pharmacokinetics of different drug formulations in both animals and humans.

Today, more ordinary people are taking an interest in tracking their mitochondrial health in order to take concrete steps to improve their overall wellness and boost longevity. Previously, such interest was a mainstay among elite athletes, scientists and biohacking enthusiasts. Why are more people choosing to have their mitochondrial health tested?

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharma company focused on inflammation and immunology, announced that Dr. Roberta Lotti of Pincell Srl has won the “Oscar of Italian Dermatology” from SIDeMaST for her research on PC111, a first-in-class anti-Fas Ligand monoclonal antibody. The study, published under the title “Blocking soluble Fas Ligand ameliorates pemphigus” , confirms PC111’s ability to block blister formation by preventing keratinocyte apoptosis in pemphigus vulgaris. Scinai holds an option to acquire Pincell and is advancing PC111 as a lead asset, emphasizing its potential as a non-immunosuppressive, disease-modifying treatment for severe autoimmune skin conditions.

HealthLynked (OTCQB: HLYK), a healthcare technology and patient engagement company, has announced a strategic partnership with Endlink, a data integration firm led by Rubén Viera. The alliance aims to enhance EMR connectivity and workflow automation across hospital systems, building on Endlink’s success in Puerto Rico, where its platform serves over 300,000 members and supports two major hospital systems. Viera, a former executive at McKesson and Greenway Health, brings over 25 years of experience in healthcare IT and will help expand HealthLynked’s capabilities in real-time data integration and patient-centered care. The collaboration also creates opportunities to deploy HealthLynked’s tools—like AI-driven insights and virtual care access—across Endlink’s client base.

Limo SF VIP (888-888-0195) announces a new premium chauffeur service offering executive travelers seamless and exclusive transportation in and around San Francisco.

InMed Pharmaceuticals (NASDAQ: INM), a pharmaceutical company developing small molecule drug candidates for diseases with high unmet medical needs, announced new preclinical data showing that INM-901 significantly reduces inflammation in ex vivo models of neuroinflammation. The compound demonstrated a dose-dependent and statistically significant reduction in pro-inflammatory cytokines IL-6, IL-1β, IL-2, KC/Gro, and inflammasome marker NLRP3—key factors in Alzheimer’s disease progression. Notably, the effects were independent of amyloid beta or tau pathology, highlighting INM-901’s broader potential in treating neurodegenerative diseases. The orally administered compound also targets CB1/CB2 receptors and PPARs and has shown improvements in cognition and behavior in long-term animal studies. InMed plans to advance INM-901 through additional preclinical and IND-enabling studies with a lead indication in Alzheimer’s disease.

Panda Hub, a mobile-first car detailing marketplace, has expanded into 15 U.S. states and 2 Canadian provinces. The platform connects vehicle owners with certified detailers for on-site interior and exterior services. Customers can book directly online and receive professional car care at their home, workplace, or other approved location. This expansion reflects Panda Hub’s ongoing mission to deliver consistent, transparent, and eco-conscious detailing services across North America.

An ongoing clinical trial at the Comprehensive Cancer Center at UC Davis seeks to find out whether fermented wheat germ could help cancer patients undergoing immunotherapy have better outcomes and live full lives, or even beat cancer.

Robotics is playing an ever-increasing role in revolutionizing healthcare . The medical industry is playing a leading role in the adoption of robotics and the pace at which these technologies are being adopted is accelerating. It is therefore not surprising that the market for medical robotics is forecast to grow from $16.6bn to $63.8bn between 2023 and 2032. Several applications of these technologies are justifying further deployment.

The opioid crisis remains one of the most persistent public health emergencies in the U.S. While state and federal initiatives have helped curb some of the worst-case trajectories, more than 100,000 Americans still die each year from drug overdoses, a significant proportion linked to synthetic opioids like fentanyl. The crisis is evolving, not disappearing, and the pharmaceutical industry continues to grapple with the challenge of balancing patient access with the need for safety and deterrence.

Not Your Basic Locksmith (817-508-2601) expands its mobile automotive locksmith services, now available across the greater Dallas-Fort Worth metroplex, including Mansfield, Irving, Keller, Bedford, and Hurst.

Psoriasis is more than just a skin condition — it’s a lifelong autoimmune disorder that disrupts daily life with painful, inflamed patches and an emotional toll that can be just as severe as the physical symptoms. Soligenix (NASDAQ: SNGX) is at the forefront of developing innovative therapies for this condition, notably SGX302 (synthetic hypericin), a novel treatment currently undergoing Phase 2a clinical trials aimed at addressing mild to moderate psoriasis.

Doylestown Auto Repair (267-279-9477) has expanded their specialized timing chain and brake replacement services for Audi vehicles, providing affordable, high-quality repairs.

Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, announced the successful commercial manufacturing process scale-up of its lead product, Aversa Fentanyl, in collaboration with Kindeva, a global CDMO specializing in drug-device combinations. Aversa Fentanyl integrates Nutriband’s AVERSA abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch and is produced at Kindeva’s U.S.-based transdermal facility. The next step involves producing clinical supplies and submitting an Investigational New Drug application to begin a human abuse liability study. Nutriband projects Aversa Fentanyl, which aims to be the world’s first abuse-deterrent opioid patch, could achieve peak U.S. sales between $80 million and $200 million, with broader global market ambitions supported by its extensive international patent portfolio.